Marco Alessandrini | CTO
Antion Biosciences

Marco Alessandrini, CTO, Antion Biosciences

Marco is Managing Director of Antion Biosciences and responsible for driving key priorities and developments of the company. After qualifying with his PhD in South Africa, Marco worked for five years in the Biotech and Pharma sectors. During this time, he led the establishment of a novel biomarker service at Synexa Life Sciences, which provided pharmacogenomic testing services to the clinical trial industry. He then transitioned to a position in Pharma at Key Oncologics where he was responsible for the design, regulatory approval and management of oncology clinical trials in South Africa. He subsequently joined the Institute for Cellular and Molecular Medicine at the University of Pretoria as a senior researcher to build on his expertise in personalized medicine. Within the framework of an international collaboration to engineer a HIV-resistant immune system, Marco relocated to Europe in 2016 to take up a position at the University of Geneva. He has since been dedicated solely to the development and clinical translation of gene-modified cell therapies for HIV and cancer. In 2018, he joined Antion Biosciences as Operations Manager, and he has since played a central role in shaping the future direction of the company. In November 2019, Marco assumed the role of Managing Director in Antion.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 13:30

Panel discussion: Rise of allogeneic cells and allo-approaches to oncology & non-oncology

·The cell types·Impact of gene editing·Cellular Persistence·Cellular phenotypes·Expansion In vivo·Possibility of retreatment·Lymphodepletion·Administration of the cells/ Amount of the cells/Local and systemic administration

Day 1: Wednesday 19th May 2021 - Cell Therapy @ 14:30

miCAR: A novel approach to creating allogeneic CAR T-cell therapies

last published: 10/May/21 08:45 GMT

back to speakers